A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years

Trial Profile

A Double-Blind, Randomized, Four-Period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Dapagliflozin; Moxifloxacin
  • Indications Bacterial infections; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Jun 2009 Results presented at ADA 2009.
    • 23 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top